资讯  教育  校园  房产  旅游  娱乐  科技  健康  财经  体育  消费  文史  书画  能源

  RSS 设为首页   加入收藏
首页 > 文传商讯 > 正文

STALICLA Translates its Novel Precision Medicine Approach for Autism Spectrum Disorder into Clinical

时间:2020-12-11 08:51:00  来源:文传商讯  作者:
 

-First precision therapeutic to be investigated in a biologically defined ASD subpopulation: ASD-Phen1 discovered and clinically validated by STALICLA-
-STP1 could provide a new therapeutic option for as many as 20% of patients with non-monogenetic causes of ASD-

GENEVA -- (BUSINESS WIRE) --

STALICLA SA, today announced first patient enrolled in its Phase 1b clinical trial with STP1, a first in class precision medicine for patients within the autism spectrum disorder (ASD) Phenotype 1 subgroup (ASD-Phen1), a novel biological subgroup identified by STALICLA’s proprietary discovery platform. STP1 is a novel combination of compounds: a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1, specifically targeting the biological dysregulations linked to ASD-Phen1.

Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders (NDDs) currently diagnosed based on core behavioral features, including persistent deficits in social communication and social interaction, restricted and repetitive patterns of behavior, interests, or activities. Significant impairment in daily functioning should also be present. Globally, ASD is highly prevalent and affects approximately 10 million patients in Europe and the United States and more throughout the world. There are no biological criteria for this diagnosis. ASD is characterized by high levels of clinical and genetic heterogeneity, supporting the existence of ASD biological subtypes requiring differential pharmacological treatment strategies.

By combining real-world patient data and its proprietary systems biology and AI-powered drug discovery platform called DEPI (Databased Endophenotyping Patient Identification), STALICLA is uncovering novel patterns of non-behavioral and biologically defined parameters amongst patients with ASD. STALICLA has already identified ASD Phenotype 1, a first subpopulation of patients with idiopathic ASD that can be identified by distinct multi-omics biomarkers. ASD Phenotype 1 is characterized by dysregulation of key intracellular pathways, transcription factors and immune factors. The most recent biomarker data related to ASD Phenotype 1 will be presented by STALICLA ahead of publication at the BRAIN Foundation Synchrony 2020 conference on December 12, 2020 (online).

“STALICLA is the first company developing precision medicine treatments for a biologically defined subgroup of patients with ASD. A diagnosis of autism must be integrated with other layers of data to capture biologically specific mechanisms, enabling the identification of precision drug candidates to improve on the outcome of clinical trials. STALICLA has built its DEPI drug discovery platform to achieve just this. By defining novel ASD phenotypes based on clinical signs and symptoms and not only on behaviors, STALICLA is creating a precision medicine approach to discovering and developing novel treatments for patients with ASD,” said Lynn Durham, M.Sc. Chief Executive Officer and founder of STALICLA.

“This Phase 1b study for STP1 marks the first time that a precision therapeutic will be investigated in patients with a non-monogenetic cause of ASD. While the trial progresses, STALICLA will continue to drive forward its proprietary and partnered programs to define additional ASD Phenotypes and advance a robust pipeline of therapeutic candidates for ASD and other NDDs,” said, Delphine Charvin, PhD, STALICLA’s Chief Scientific Officer.

“Despite the high prevalence of neurodevelopmental disorders in the U.S. and Europe, most NDDs are diagnosed and treated based on behavioral-based classification systems alone,” said Study Investigator, Craig Erickson, MD, Cincinnati Children’s Hospital Medical Center. “I look forward to investigating the potential of STP1 in the first clinically validated subpopulation of patients with idiopathic ASD.”

The double-blind, placebo-controlled, first-in-human study is being conducted at Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. The primary objective of the trial is to evaluate the safety and tolerability of a two-week oral treatment with STP1 in adult patients who match the ASD-Phen1 clinical criteria. Two ascending dose cohorts of approximately 12 patients each will be enrolled. The study will also assess the pharmacokinetic and pharmacodynamic effects of STP1 and includes exploratory efficacy surrogate endpoints.

About ASD Phenotype 1
ASD Phenotype 1 (ASD-Phen1) is a subgroup of patients with autism spectrum disorder which has been identified by STALICLA’s platform and includes as many as 20% of the total ASD population with a non-monogenetic cause. ASD-Phen1 was first validated by an observational clinical trial conducted at the Greenwood Genetic Center (South Carolina, U.S.). ASD-Phen1 criteria were applied to a cohort of 313 patients with ASD. The study led to the identification of patients who matched the required clinical criteria and represented the first clinical validation of the ASD-Phen1 subgroup. Further biological characterization of ASD-Phen1 revealed a specific biological signature, or “fingerprint,” of the patient subgroup that was consistent with the signature proposed by STALICLA’s DEPI drug discovery platform.

About STP1
STALICLA’s investigational new drug, named STP1, is a first-in-class precision medicine being developed as part of the company’s proprietary pipeline for the treatment of ASD for patients within the Phenotype 1 subgroup (ASD-Phen1). STP1 is a novel combination of a pan-PDE inhibitor with anti-inflammatory properties and a modulator of NKCC1. STP1 was identified as a potential match for ASD Phenotype 1 using the DEPI platform, addressing ASD-Phen1 biological dysfunctions and limiting the emergence of compensatory disease pathways. In addition, STP1 has shown a good safety profile in nonclinical toxicology studies. Taken individually, both compounds have also demonstrated good clinical safety and tolerability profiles over a broad range of doses and non-ASD indications.

About STALICLA
STALICLA is reframing neurodevelopmental disorders on the basis of novel insights into their biological underpinnings. By combining real-world patient data and a proprietary systems biology and AI-powered drug discovery platform called DEPI, STALICLA is uncovering novel patient subgroups, enabling targeted clinical development and fueling a rich pipeline of precision therapies. STALICLA has formed a global network of partnerships to bring the first precision medicine treatments to patients with NDDs as efficiently as possible with an initial focus on autism spectrum disorder (ASD). https://stalicla.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005723/en/

CONTACT:

STALICLA
Lynn Durham
lynn.durham@stalicla.com
0041 (0) 78 812 68 98

Media
Kari Watson
MacDougall
kwatson@macbiocom.com

 
 
 
上一篇:阿联酋的EDGE成为跻身全球25大军火公司之列的首家中东公司
下一篇:ABB appoints Carolina Granat as Chief Human Resources Officer
 
 
 
 
推荐资讯
中国浓香白酒核心产区沉淀一杯出“大国浓香”五粮液
中国浓香白酒核心产区
电影《钢铁意志》今日全国公映 青年歌唱家汤非献唱主题曲
电影《钢铁意志》今日
长安马自达好不好 恩施消费者有话说
长安马自达好不好 恩施
年轻人的座驾 创酷RS恩施受追捧
年轻人的座驾 创酷RS恩
栏目更新
  • Yokogawa攜手Shell,共同推動機器人與AI技術
  • NEL动物心脏医疗中心成功完成全球首例犬类复
  • Prime Success发表声明纽约州法院认可我们作
  • 科兴董事会胜诉,纽约法院驳回尚珹资本/Pri
  • TH Global Capital 连续第三年荣膺第16届年
  • SLB宣布召开2025年第二季度业绩电话会议
  • 科威特在2025年大阪世博会举办国庆日庆典,
  • Kioxia扩展第八代BiCS FLASH SSD产品组合,
  • 横河电机携手壳牌,共同开发用于工厂维护的
  • Combined Shareholders’ Meeting of June
  • 栏目热门
  • RNA sequencing transformed: Oxford Nanop
  • Featurespace募得2500万英镑以推动国际增长
  • 众多知名大厨将云集东京,为期10个月的千载
  • Tigo推出具有增强光伏系统监控、设计布局和
  • 穆迪分析为CreditLens解决方案新增重要的自
  • DOCOMO将以OEM的方式为台湾FET提供相册服务
  • 新白皮书呼吁让车辆自动驾驶和安全驾驶辅助
  • 60家挑战赛获奖者蓄势待发,迎接2019年香港
  • Velodyne在NVIDIA DRIVE平台展示可实现丰富
  • 阿联酋大爱基金会2018年人道主义举措造福11
  •  
     

     
     
    网站声明 | 网站简介 | 网站导航 | 频道招商 | 联系方式 | 友情链接
    www.hlwang.net 华鲁网